Global pharma major Lupin Limited (Lupin) today announced that it has launched Rivaroxaban Tablets USP, 2.5 mg, following the final approval of its Abbreviated New Drug Application from the USFDA.
Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto® Tablets, 2.5 mg of Janssen Pharmaceuticals and indicated:
– to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD)
– to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD.
Rivaroxaban Tablets USP, 2.5 mg (RLD Xarelto®) had estimated annual sales of USD 446 million in the U.S. (IQVIA MAT January 2025).
This walk-in interview is for positions at Optimus Pharma Pvt Ltd (Formulations Division). Job Details…
Macleods Pharmaceuticals is hosting a walk-in interview drive for its R&D facility in Mumbai. Job…
This flyer outlines a walk-in interview drive for Shilpa Medicare in Hyderabad. 📅 Interview Schedule…
Neuland Laboratories is hosting walk-in interviews in Hyderabad on June 20, 2026. Here are the…
Hetero Biopharma Limited is hosting walk-in interviews for pharmaceutical manufacturing roles. Key Event Details Dates:…
This image is an advertisement for a walk-in interview hosted by Tirupati Medicare Ltd. Job…